ContraFect Corporation

OTCPK:CFRX Stock Report

Market Cap: US$676.1k

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

ContraFect Past Earnings Performance

Past criteria checks 0/6

ContraFect's earnings have been declining at an average annual rate of -17.2%, while the Biotechs industry saw earnings growing at 17.4% annually.

Key information

-17.23%

Earnings growth rate

34.11%

EPS growth rate

Biotechs Industry Growth17.04%
Revenue growth raten/a
Return on equityn/a
Net Marginn/a
Last Earnings Update30 Sep 2023

Recent past performance updates

No updates

Recent updates

Seeking Alpha • Aug 15

Contrafect GAAP EPS of -$0.46 misses by $0.13

Contrafect press release (NASDAQ:CFRX): Q2 GAAP EPS of -$0.46 misses by $0.13. As of June 30, 2022, ContraFect had cash, cash equivalents and marketable securities of $27.3 million. Shares +4% PM
Seeking Alpha • Jul 13

ContraFect sinks ~76% as data safety board recommends ending co's DISRUPT trial

Shares of micro-cap biotech ContraFect (NASDAQ:CFRX) plunged ~76% after hours as a data safety board recommended that the company's DISRUPT trial be stopped. The Data Safety and Monitoring Board (DSMB) recommended such an action "because the conditional power of the study was below the pre-specified threshold for futility," CFRX said in a statement on Wednesday. ContraFect's (CFRX) phase 3 DISRUPT trial was investigating the company's lysin exebacase in about 350 patients with complicated S. aureus bacteremia, which is the presence of the bacteria Staphylococcus aureus in the bloodstream. The DSMB's recommendation was based on an interim analysis of the clinical response rate of 84 patients in the trial at day 14, which was also the main goal of the study. "While further review of the data is ongoing, the company is initiating steps to notify investigators that patient enrollment in the trial is being stopped based on the DSMB recommendation," CFRX added.
Analysis Article • Jun 29

ContraFect (NASDAQ:CFRX) Is In A Good Position To Deliver On Growth Plans

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Analysis Article • Dec 25

Is ContraFect (NASDAQ:CFRX) In A Good Position To Invest In Growth?

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Seeking Alpha • Sep 15

ContraFect: Non-Antibiotic Alternative That Could Disrupt The Antibiotic Market

CFRX is developing a medicine to treat bacterial infections without using an antibiotic. Phase 2 trials have shown outstanding data against MRSA infections, and reduced hospital time. The company has decent cash, but may need more.
Analysis Article • Aug 18

We're Keeping An Eye On ContraFect's (NASDAQ:CFRX) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • May 01

Is ContraFect (NASDAQ:CFRX) In A Good Position To Deliver On Growth Plans?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Mar 09

Are Institutions Heavily Invested In ContraFect Corporation's (NASDAQ:CFRX) Shares?

The big shareholder groups in ContraFect Corporation ( NASDAQ:CFRX ) have power over the company. Insiders often own a...
Analysis Article • Jan 15

Is ContraFect (NASDAQ:CFRX) In A Good Position To Invest In Growth?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Nov 24

What Type Of Shareholders Make Up ContraFect Corporation's (NASDAQ:CFRX) Share Registry?

A look at the shareholders of ContraFect Corporation (NASDAQ:CFRX) can tell us which group is most powerful...

Revenue & Expenses Breakdown

How ContraFect makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

OTCPK:CFRX Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 230-241218
30 Jun 230-361225
31 Mar 230-461237
31 Dec 220-651245
30 Sep 220-601351
30 Jun 220-481349
31 Mar 220-351240
31 Dec 210-201236
30 Sep 210-221232
30 Jun 210-141228
31 Mar 210-261126
31 Dec 200-281223
30 Sep 200-321119
30 Jun 200-411120
31 Mar 200-321119
31 Dec 190-131018
30 Sep 1903921
30 Jun 1904921
31 Mar 190-7922
31 Dec 180-38922
30 Sep 180-48920
30 Jun 180-46919
31 Mar 180-28918
31 Dec 170-16917
30 Sep 170-101017
30 Jun 170-191118
31 Mar 170-261122
31 Dec 160-291122
30 Sep 160-37923
30 Jun 160-321020
31 Mar 160-291017
31 Dec 150-251015
30 Sep 150-221012
30 Jun 150-331011
31 Mar 150-3489
31 Dec 140-3589
30 Sep 140-4179
30 Jun 140-2969
31 Mar 140-2479
31 Dec 130-2479
30 Sep 130-19710
30 Jun 130-20712
31 Mar 130-20712

Quality Earnings: CFRX is currently unprofitable.

Growing Profit Margin: CFRX is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: CFRX is unprofitable, and losses have increased over the past 5 years at a rate of 17.2% per year.

Accelerating Growth: Unable to compare CFRX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CFRX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-42.7%).

Return on Equity

High ROE: CFRX's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/12/04 12:07
End of Day Share Price 2023/12/04 00:00
Earnings2023/09/30
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

ContraFect Corporation is covered by 11 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Esther Lannie HongBrean Capital Historical (Janney Montgomery)
Louise ChenCantor Fitzgerald & Co.
Keay NakaeChardan Capital Markets, LLC